Finerenone Improves Albuminuria via MR-TRPC Signaling in Diabetic Kidney Disease

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances2026
2. 21403-P: Effects of Finerenone on Chronic Kidney Disease in Patients with Type 2 Diabetes: Association with Metabolic Dysfunction–Associated Steatotic Liver Disease2026
3. 3Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety2025
4. 4Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and Telmisartan2025
5. 5Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease2025